Chemotherapy and Bevacizumab With or Without Radiofrequency Ablation in Treating Unresectable Liver Metastases in Patients With Colorectal Cancer

You may be eligible if

• DISEASE CHARACTERISTICS:
• Unresectable liver metastases secondary to colorectal adenocarcinoma, including:
• * Metastases that cannot be radically resected due to size, location, or number of deposits
• * Metastases invading right and left branches of hepatic artery or portal vein
• * Metastases extended to the 3 main hepatic veins
• No detectable extra-hepatic disease
• Fewer than 10 metastatic deposits on liver
• Total metastatic involvement of liver no more than 50%
• Adequate treatment of all metastatic lesions deemed possible either by radiofrequency interstitial ablation (RFA) alone or by a combination of resection of resectable lesions and RFA of the remaining unresectable lesions
• * Maximum diameter of 4 cm for lesions to be treated with RFA
• * No maximum diameter of lesions to be resected as long as negative resection margins are obtainable
• If synchronous liver metastases, must have undergone prior resection of primary tumor
• PATIENT CHARACTERISTICS:
• Age
• 18 to 80
• Performance status
• WHO 0-1
• Life expectancy
• Not specified
• Hematopoietic
• Absolute neutrophil count greater than 1,500/mm\^3
• Platelet count greater than 100,000/mm\^3
• No bleeding disorder or coagulopathy or need for full-dose anticoagulation
• Hepatic
• Bilirubin less than 3 times upper limit of normal (ULN)
• Alkaline phosphatase less than 3 times ULN
• Renal
• Creatinine less than 2 times ULN
• Protein \< 0.5 g/24 hr urine collection if proteinuria positive by dipstick
• Cardiovascular
• No uncontrolled congestive heart failure
• No uncontrolled angina pectoris
• No uncontrolled hypertension
• No uncontrolled arrhythmia
• No myocardial infarction within the past 12 months
• No cerebrovascular accident or transient ischemic attack within the past 6 months
• Other
• Not pregnant or nursing
• Fertile patients must use effective contraception
• No greater than grade 1 peripheral neuropathy
• No significant neurologic or psychiatric disorder
• No active infection
• No contraindication to the use of fluorouracil, leucovorin calcium, oxaliplatin, or bevacizumab
• No other malignancy within the past 10 years except nonmelanoma skin cancer or carcinoma in situ of the cervix
• PRIOR CONCURRENT THERAPY:
• Biologic therapy
• Not specified
• Chemotherapy
• No prior chemotherapy except for metastatic disease confined to the liver
• * Prior fluorouracil, leucovorin calcium, and oxaliplatin allowed if administered for at least 3 courses (2 weeks each) but no longer than 3 months with at least stabilization of disease achieved
• Prior adjuvant chemotherapy for primary cancer allowed except for patients who received oxaliplatin and have been diagnosed with metastatic disease within 12 months after completion of adjuvant treatment
• Endocrine therapy
• Not specified
• Radiotherapy
• Not specified
• Surgery
• More than 28 days since major surgery or open biopsy past 28 days
• More than 28 days since significant traumatic injury
• Other
• No other concurrent investigational treatment
• No other concurrent anticancer therapy